Putting the name of this imperious disease in the title of my homily places a weighty responsibility on me. Who am I to attempt to put forth relevant information and sensible opinions on this topic, the mere mention of which makes most normal folk distinctly uneasy? But I probably pay more attention to […]
Articles
Is this going to be good news, or bad news, or somewhere in between? On balance, I would say good news, simply because the research and investigation is going on at an intense pace. Currently there are 1,903 clinical trials underway at some stage, in the US and all over the world. When I first […]
No, these bits won’t be about Melania’s kidney ailment nor yet about what Meghan wore for The Wedding. I wish them both luck – they’ll need it!. However, there continue to be developments on the medical and health-care fronts that may matter to us a good deal more than the doings of those ladies. […]
Welcome back from vacation, me! There’s no question what ad should be covered first as I brush the sand off my feet and turn up the heat here at Gumshoe HQ… it’s the pitch from Marc Lichtenfeld for his Lightning Trend Trader over at Oxford Club, and the “special report” he’s dangling as bait. That […]
[Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and more recent comments here.] Picture the gurbling fumaroles of Yellowstone: from the late 1990’s and on into […]
The Gain from Pain Mainly Explained: Fire Walk with Me[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. This article is third in a series on pain. You can see the first part here, and second part here. His words and opinions are his own, and he has agreed to our trading restrictions. Enjoy!] It’s the stuff of bucket lists: eating fugu […]
[Ed. note: Michael Jorrin, who we like to call “Doc Gumshoe,” is not a doctor, he is a longtime medical writer who contributes pieces for us that we hope give a good background or perspective on medical issues (and marketing) for those of us who are as overwhelmed with “live to 150” promises as we […]
Today we’re sharing another piece from our medical contributor, “Doc Gumshoe” — we have added the stock tickers to the companies he mentions for your researching convenience, but this survey of the state of cancer research — which will hopefully be good background help to folks trying to understand the basic science behind pitches for […]
As promised, we’re following up with the rest of the picks that Stephen Leeb (sorry, Dr. Stephen Leeb) is pitching as his “MCR” Plan. If you missed our first entry as we began demystifying this particular ad, you can see it here — the short version is, he’s touting dividend paying stocks in the medical […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Thin-skinned with anger issues, yes. Don't know what "man-child" means. Con artist? No way. I've been investing in biote...
$DNLI Any thoughts in here about Denali? I've been following it for a year or so waiting for the IPO. I always loved Gen...
$ HALO LONG Halozyme Therapeutics (HALO) announces the initiation of a multi-arm clinical trial evaluating PEGPH20,...
$MRK & much more... NEW http://e.endpointsnews.com/t/ViewEmail/t/A537ED71EDB429B5/2F80028A944F69C925D77A725F39070E...
$best bio CEOs - I would LOVE to have you start a discussion on this topic. I've been investing in biotech since the Gen...
I too missed the Dr. exiting..I did call the firm and they do have a back up plan just in case it is needed..the managem...
I can't share any experience with that particular newsletter (I despise $1500/year newsletters in general), but I can sh...
From what I have read, Genentech is only now launching a Phase 1 study in their DLK inhibitor, GDC-0134. I have the ut...
I wrote today about a different Alzheimer's Disease drug being tested in mice, not the one Doc Gumshoe mentioned. It als...
$AXSM long - Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors http://phx.corporate-ir.net/phoenix...
$TGTX long, Genentech needs to protect $7 billion a year in Rituxan sales. It's bigger for them than Avastin. They can b...
$reph and $xene question/clarification; $reph has successfully completed both ph 3's and safety study, and will be s...
Thanks for kind words, I feel like a rat for doing it but I am going to send you an email, please ignore as you like wri...
Doc, jking and fellow Gummies: Fovista is dead. Final analysis of the two completed pivotal phase 3 studies of fovi...
Doc, there is another name that Rodman and Renshaw is also bullish on and you have made both positive and negative comme...
Genentech oncology head jumps ship to Bellicum as CEO: https://t.co/4r0RqVu2uM...
Andrew L. Salzman, M.D., Chief Executive Officer and Chief Medical Officer Dr. Salzman is a physician, scientist, inven...
Like this spot to enter IMDZ here after recent secondary. Doc if I recall you liked IMDZ platforms when we discussed th...
$BLRX today announced collaboration with Genentech, Phase 1b BL-8040 in combination with Atezolizumab, Genentech's anti...
Doc Kss, would you think this company Epic Science would be in direct competition with BIOC ? They have a impressive cli...
TGIF 1 more day....please let's stay focused. $tril vol off the charts last 3 days on strength. Maybe Uncle Irv gives u...
Interesting Article Genentech's Trojan horse destroys cocooned Staphylococcus aureus http://davidusharauli.blogspot.c...
Antibody Engineering & Therapeutics 2015 http://www.ibclifesciences.com/AntibodyEng/overview.xml A couple of audio cli...
Xenon (XENE) achieves milestone with Genentech partnership. http://finance.yahoo.com/news/xenon-pharmaceuticals-achieve...
The Biotech Book Shelf? Are you kidding me? What a great idea for a thread, Anamorph! Thanks for your wonderful post...
I know there are Gummies who, like me, find Dr KSS's essays as valuable for the intellectual stimulation they provide as...
Genentech brain trust leaves company. http://www.forbes.com/sites/matthewherper/2015/05/14/former-genentech-researchers...
DR. KSS - I have been investing in biotech since Genentech came public and have for all those years read thousands of pr...
XENE: Xenon Pharmaceuticals Appoints Dr. Richard H. Scheller to Its Board of Directors BURNABY, British Columbia, Ma...
Michael, I have never read such an excellent synopsis of the current state of oncology research in all that time and le...
To Joe Schelble: about Curis($CRIS). I could see this one running another 20- 25 percent from here over the near term. W...
I'd meant to comment during this past very busy week about Newlink Genetics ($NLNK). If you saw it spike mightily this w...
Has anyone mentioned Immunogen? Been in a slow steady decline with a reversal today. I don't see any news. Just looks...
I did some DD on the Solazyme website and looking at some existing SA articles--it is a very intriguing story. The alga...
Thanks Eyedoc for your great sleuthing on Avalanche Bio. I would like to add that the CEO of this company, Tom Chalberg...
Google's Calico makes some important hires. An attempt to develop anti-aging treatments. http://www.fiercebiotech.com...
Thanks, Dr.KSS. This is not surprising. I know that this might give GILD longs a mild bit of PAT, so let me give it a li...
Senesco Announces New CEO SNTI announced the appointment of Ronald A. Martell as chief executive officer at the 2014 ...
Perhaps this explains a bit of the interest: Agios brought Dr. Chris Bowden on board to oversee the company's clinica...
Did he tell what the Cancer drug he was pushing? Wonder if the company is Roche or Genentech?...
Bought SGEN at just over $12 a year ago. My wife is in the biotech field. Some highly regarded execs from Genentech are ...
I own shares of Sangamo Biosciences (SGMO). Sangamo is focused on the research and commercial development of engineered ...